Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG-1701 in B-Cell Malignancies
NCT03671590Phase 1Terminated
- Sponsor
- TG Therapeutics, Inc.
- Start
- Sep 2018
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of edralbrutinib in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) (3 arms), sponsored by TG Therapeutics, Inc. Primary endpoint: Maximum Tolerated Dose. Started Sep 2018; status: terminated.
02
Drugs
edralbrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03671590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03671590.